Indications
Vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by Vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3-ITD positive.
Composition
- Active substance
- quizartinib dihydrochloride
- International name (INN)
- quizartinib
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Vanflyta
- Active substance
- quizartinib dihydrochloride
- ATC code
- L01EX11
- Therapeutic area
- Leukemia, Myeloid